U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07005024) titled 'DOAC - Dosing Options in AntiCoagulation Prophylaxis' on May 26.
Brief Summary: Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience.
This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see ...